Literature DB >> 30815833

FDG-PET in possible cardiac sarcoidosis: Right ventricular uptake and high total cardiac metabolic activity predict cardiovascular events.

Heikki Tuominen1, Atte Haarala2, Antti Tikkakoski2, Mika Kähönen2,3, Kjell Nikus3,4, Kalle Sipilä2.   

Abstract

BACKGROUND: Cardiac involvement accounts for the majority of morbidity and mortality in sarcoidosis. Pathological myocardial fluorodeoxyglucose (FDG)-uptake in positron emission tomography (PET) has been associated with cardiovascular events and quantitative metabolic parameters have been shown to add prognostic value. Our aim was to study whether the pattern of pathological cardiac FDG-uptake and quantitative parameters are able to predict cardiovascular events in patients with suspected cardiac sarcoidosis (CS).
METHODS: 137 FDG-PET examinations performed in Tampere University Hospital were retrospectively analyzed visually and quantitatively. Location of pathological uptake was noted and pathological metabolic volume, average standardized uptake value (SUV), and total cardiac metabolic activity (tCMA) were calculated. Patients were followed for ventricular tachycardia, decrease in left ventricular ejection fraction, and death.
RESULTS: Eleven patients had one or more cardiovascular events during the follow-up. Five patients out of 12 with uptake in both ventricles had an event during follow-up. Eight patients had high tCMA (> 900 MBq) and three of them had a cardiovascular event. Right ventricular uptake and tCMA were significantly associated with cardiovascular events during follow-up (P-value .001 and .018, respectively).
CONCLUSIONS: High tCMA and right ventricular uptake were significant risk markers for cardiac events among patient with suspected CS.

Entities:  

Keywords:  PET; Sarcoid heart dusease; inflammation; metabolism imaging agents

Mesh:

Substances:

Year:  2019        PMID: 30815833      PMCID: PMC7920884          DOI: 10.1007/s12350-019-01659-2

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  24 in total

1.  Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis.

Authors:  Chiung-Zuan Chiu; Satoshi Nakatani; Guican Zhang; Teruo Tachibana; Fumio Ohmori; Masakazu Yamagishi; Masafumi Kitakaze; Hitonobu Tomoike; Kunio Miyatake
Journal:  Am J Cardiol       Date:  2005-01-01       Impact factor: 2.778

2.  Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging.

Authors:  Paco E Bravo; Ganesh Raghu; David G Rosenthal; Shana Elman; Bradley J Petek; Laurie A Soine; Jeffrey H Maki; Kelley R Branch; Sofia C Masri; Kristen K Patton; James H Caldwell; Eric V Krieger
Journal:  Int J Cardiol       Date:  2017-03-10       Impact factor: 4.164

3.  Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on 18F-FDG PET Scans for Suspected Cardiac Sarcoidosis.

Authors:  Brett W Sperry; Balaji K Tamarappoo; Jorge D Oldan; Omair Javed; Daniel A Culver; Richard Brunken; Manuel D Cerqueira; Rory Hachamovitch
Journal:  JACC Cardiovasc Imaging       Date:  2017-08-16

Review 4.  Arrhythmias in cardiac sarcoidosis: diagnosis and treatment.

Authors:  Pablo B Nery; Eugene Leung; David H Birnie
Journal:  Curr Opin Cardiol       Date:  2012-03       Impact factor: 2.161

5.  18F-FDG-PET in Finnish patients with clinical suspicion of cardiac sarcoidosis: Female sex and history of atrioventricular block increase the prevalence of positive PET findings.

Authors:  Heikki Tuominen; Atte Haarala; Antti Tikkakoski; Pasi Korkola; Mika Kähönen; Kjell Nikus; Kalle Sipilä
Journal:  J Nucl Cardiol       Date:  2017-06-05       Impact factor: 5.952

6.  Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone.

Authors:  Y Yazaki; M Isobe; M Hiroe; S Morimoto; S Hiramitsu; T Nakano; T Izumi; M Sekiguchi
Journal:  Am J Cardiol       Date:  2001-11-01       Impact factor: 2.778

7.  Prognostic value of fluorine-18 fluoro-2-deoxyglucose positron emission computed tomography in patients with unexplained atrioventricular block.

Authors:  Tamiruddin A Danwade; Soumen Devidutta; Abhijeet B Shelke; Daljeet Kaur Saggu; Sachin D Yalagudri; Chennapragada Sridevi; Nallamala Krishna Reddy; Calambur Narasimhan
Journal:  Heart Rhythm       Date:  2017-10-20       Impact factor: 6.343

8.  Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis.

Authors:  Ron Blankstein; Michael Osborne; Masanao Naya; Alfonso Waller; Chun K Kim; Venkatesh L Murthy; Pedram Kazemian; Raymond Y Kwong; Michifumi Tokuda; Hicham Skali; Robert Padera; Jon Hainer; William G Stevenson; Sharmila Dorbala; Marcelo F Di Carli
Journal:  J Am Coll Cardiol       Date:  2013-10-16       Impact factor: 24.094

9.  Semi-quantitative metabolic values on FDG PET/CT including extracardiac sites of disease as a predictor of treatment course in patients with cardiac sarcoidosis.

Authors:  Mitsutomi Ishiyama; Laurie A Soine; Hubert J Vesselle
Journal:  EJNMMI Res       Date:  2017-08-18       Impact factor: 3.138

10.  Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction: Risk Stratification Using Cardiovascular Magnetic Resonance.

Authors:  Gillian Murtagh; Luke J Laffin; John F Beshai; Francesco Maffessanti; Catherine A Bonham; Amit V Patel; Zoe Yu; Karima Addetia; Victor Mor-Avi; Joshua D Moss; D Kyle Hogarth; Nadera J Sweiss; Roberto M Lang; Amit R Patel
Journal:  Circ Cardiovasc Imaging       Date:  2016-01       Impact factor: 7.792

View more
  6 in total

1.  Prognostic insights of molecular imaging in cardiac sarcoidosis.

Authors:  Riccardo Laudicella; Fabio Minutoli; Sergio Baldari
Journal:  J Nucl Cardiol       Date:  2019-04-03       Impact factor: 5.952

2.  Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM.

Authors:  Brett W Sperry; Timothy M Bateman; Esma A Akin; Paco E Bravo; Wengen Chen; Vasken Dilsizian; Fabien Hyafil; Yiu Ming Khor; Robert J H Miller; Riemer H J A Slart; Piotr Slomka; Hein Verberne; Edward J Miller; Chi Liu
Journal:  J Nucl Cardiol       Date:  2022-07-21       Impact factor: 3.872

Review 3.  The role of PET in the management of sarcoidosis.

Authors:  Robert J Vender; Hamad Aldahham; Rohit Gupta
Journal:  Curr Opin Pulm Med       Date:  2022-07-16       Impact factor: 2.868

4.  Right Ventricular Abnormalities on Cardiovascular Magnetic Resonance Imaging in Patients With Sarcoidosis.

Authors:  Pratik S Velangi; Ko-Hsuan Amy Chen; Felipe Kazmirczak; Osama Okasha; Lisa von Wald; Henri Roukoz; Afshin Farzaneh-Far; Jeremy Markowitz; Prabhjot S Nijjar; Maneesh Bhargava; David Perlman; Mehmet Akçakaya; Chetan Shenoy
Journal:  JACC Cardiovasc Imaging       Date:  2020-01-15

Review 5.  Imaging Atherosclerosis by PET, With Emphasis on the Role of FDG and NaF as Potential Biomarkers for This Disorder.

Authors:  Michael Mayer; Austin J Borja; Emily C Hancin; Thomas Auslander; Mona-Elisabeth Revheim; Mateen C Moghbel; Thomas J Werner; Abass Alavi; Chamith S Rajapakse
Journal:  Front Physiol       Date:  2020-10-22       Impact factor: 4.566

6.  Incidental anal 18fluorodeoxyglucose uptake: Should we further examine the patient?

Authors:  Anne-Sophie Moussaddaq; Charlène Brochard; Xavier Palard-Novello; Etienne Garin; Timothée Wallenhorst; Eric Le Balc'h; Alexandre Merlini L'heritier; Thomas Grainville; Laurent Siproudhis; Astrid Lièvre
Journal:  World J Clin Cases       Date:  2020-09-06       Impact factor: 1.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.